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a  b  s  t  r  a  c  t
Efforts  to reverse  the  pathologic  consequences  of  vulnerable  plaques  are  often  stymied  by  the  complex
treatment  resistant  pro-inﬂammatory  environment  within  the  plaque.  This  suggests  that  pro-atherogenic
stimuli,  such  as LDL  cholesterol  and high  fat diets  may  impart  longer  lived  signals  on  (innate)  immune
cells  that  persist  even  after  reversing  the  pro-atherogenic  stimuli.  Recently,  a  series  of  studies  challenged
the  traditional  immunological  paradigm  that  innate immune  cells  cannot  display  memory  characteris-
tics.  Epigenetic  reprogramming  in these  myeloid  cell  subsets,  after  exposure  to certain  stimuli,  has  been
shown  to alter  the  expression  of genes  upon  re-exposure.  This  phenomenon  has  been  termed  trained
innate  immunity  or innate  immune  memory.  The  changed  responses  of ‘trained’  innate  immune  cells
can  confer  nonspeciﬁc  protection  against  secondary  infections,  suggesting  that  innate  immune  mem-
ory  has  likely  evolved  as  an ancient  mechanism  to  protect  against  pathogens.  However,  dysregulated
processes  of immunological  imprinting  mediated  by  trained  innate  immunity  may  also  be  detrimental
under  certain  conditions  as  the  resulting  exaggerated  immune  responses  could  contribute  to  autoimmune
and  inﬂammatory  diseases,  such  as atherosclerosis.  Pro-atherogenic  stimuli  most  likely cause  epigenetic
modiﬁcations  that persist  for  prolonged  time  periods  even  after the  initial  stimulus  has  been  removed.
In this  review  we  discuss  the concept  of trained  innate  immunity  in  the  context  of a hyperlipidemic
environment  and  atherosclerosis.  According  to this  idea  the  epigenome  of  myeloid  (progenitor)  cells is
presumably  modiﬁed  for  prolonged  periods  of  time,  which,  in turn,  could  evoke  a  condition  of  continuous
immune  cell  over-activation.
©  2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
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1. Atherosclerosis, a persistent inﬂammatory disease
Cardiovascular diseases (CVD), including stroke, and myocar-
dial infarction, are the leading cause of mortality worldwide and
together are responsible for approximately 17 million deaths per
year [1]. The vast majority of cardiovascular events are caused
by the rupture or erosion of atherosclerotic plaques in the arte-
rial wall and the subsequent formation of an occluding thrombus.
Traditionally, atherosclerosis is regarded as a disease of the devel-
oped Western Society, driven by the major classical risk factors
dyslipoproteinemia, hypertension, diabetes, obesity, smoking, and
a sedentary lifestyle. Interestingly, however, the development of
atherosclerosis is not restricted to patients with a Western lifestyle.
In a recent study, CT-scanning revealed signs of atherosclerosis in
a third of mummies from several ancient populations, even in non-
smoking populations that had an almost entirely marine diet [2].
These observations ﬁt the paradigm shift in the early nineties that
atherosclerosis is more than simply a vascular cholesterol storage
disease, and that chronic low-grade vascular inﬂammation trig-
gered by the deposited material could contribute to atherogenesis
[3]. The inﬂammatory nature of atherosclerotic plaques was  already
recognized in the nineteenth century by Virchow [4], who wrote:
“In some, particularly violent cases the softening manifests itself
even in the arteries not as the consequence of a really fatty process,
but as a direct product of inﬂammation”.
In the last ten years, several novel non-traditional risk factors
for atherosclerosis have been identiﬁed that are all associated with
activation of the immune system. These include chronic inﬂamma-
tory diseases such as rheumatoid arthritis, gout, psoriatic arthritis,
and ankylosing spondylitis, as well as infections with bacteria or
viruses, such as Chlamydia pneumonia, Porphyromonas gingivalis
and human immunodeﬁciency virus (HIV) [5]. In addition, acute car-
diovascular events occur more frequently in the weeks following
an acute infection, such as pneumonia [6]. Recently, also cardio-
vascular events itself, such as myocardial infarction [7] or stroke
were described to drive subsequent acceleration of atherosclerosis
throughout the vascular system [8]. Finally, recent experimental
evidence indicates that changes in diet and in dietary composition
are able to directly inﬂuence lymphoid organs, thus profoundly and
continuously inﬂuencing immune responses and the development
of inﬂammatory and autoimmune diseases [9].
Although it is now well established that inﬂammation plays
an essential role in the initiation, progression, and destabiliza-
tion of atherosclerotic plaques, the mechanisms that drive the
persistent non-resolving inﬂammation in the vessel wall remain
incompletely understood. Macrophages are the most abundant
inﬂammatory cells present in atherosclerotic plaques. Cells of the
adaptive immune system such as T and B lymphocytes are also
present, but in lower numbers. Evidence is rapidly accumulating
that innate immune cells can adopt a persistent pro-inﬂammatory
phenotype after brief exposure to a variety of stimuli, a phe-
nomenon that has been termed ‘trained innate immunity’ [10].
In this review, we discuss the concept that trained immunity
contributes to the development of atherosclerosis, both in the set-
ting of traditional cardiovascular risk factors, and in the setting of
non-traditional risk factors, such as acute and chronic infections,
and non-infectious chronic inﬂammatory disorders. In addition,
it might well be that elevated dietary fats and consequently an
alteration of the gut microbiota, impact immune homeostasis (dys-
balance between inﬂammatory and tolerogenic processes), thus
inducing a long-term epigenetic reprogramming of innate immune
cells.
2. The innate immune system and atherosclerosis
Within atherosclerotic plaques, macrophages are the most
abundant subset of leukocytes. Arterial resident macrophages
are derived from embryonic CX3CR1+ precursors and from bone
marrow-derived monocytes that colonize the tissue immedi-
ately after birth [11,12]. During atherogenesis, arterial plaque
macrophages are sustained by local proliferation, but also
by recruitment of Ly6Chigh monocytes [13]. Monocytes and
macrophages are critically promoting the initiation, progression,
and destabilization of atherosclerotic plaques by several mecha-
nisms [14,15]. In the early stages of atherosclerosis, macrophages
contribute to the clearance of reactive lesional oxidized low-
density lipoprotein (oxLDL) particles through scavenger receptor
A (SR-A) and CD36 mediated uptake. In later stages, macrophages
are impaired in their phagocytic functionality due to intracel-
lular accumulation and defective efﬂux of oxLDL. Foam cell
macrophages undergo apoptosis due to cellular stress and inﬂam-
matory responses, a process, which ultimately contributes to the
formation of the pro-thrombotic necrotic core that characterizes
mature atherosclerotic plaques. Damage Associated Molecular Pat-
ters (DAMPs), which accumulate in the atherosclerotic plaques,
represent a source of endogenous danger ligands that can further
activate macrophages by binding to speciﬁc Pattern Recognition
Receptors (PRR), such as membrane-bound Toll Like Receptors
(TLR), SR, and intracellular NOD-like receptors (NLRs) [16]. Multi-
ple pro-inﬂammatory triggers could hence cause an inﬂammatory
milieu in the plaque. In addition, even the phase transition of
cholesterol can cause inﬂammation as cholesterol crystals can
activate the Nlrp3 (NOD-, LRR- and pyrin domain-containing 3)
inﬂammasome, triggering the secretion of pro-inﬂammatory IL-
1 and IL-18 [17]. Finally, lesional macrophages contribute to the
remodeling of atherosclerotic plaques into a rupture-prone unsta-
ble phenotype by the production of proteases, such as matrix
metalloproteinases [18]. Overall, plaque macrophages display a
marked phenotypic heterogeneity [19], which is dictated by the
composition of the local DAMPs that are present in the speciﬁc
environment during different stages of plaque development.
Several studies have shown that hypercholes-
terolemia considerably increases the number of circulating
Ly6Chigh pro-inﬂammatory monocytes in mice (or the
CD14++CD16−/CD14++CD16+ equivalent in humans), thereby
accelerating atherosclerosis [20,21]. Additionally, an acute
myocardial infarction, stroke or sepsis can accelerate subsequent
atherosclerosis by inducing monocytosis [7,22]. Which factors
are driving monocytosis in the context of a hypercholesterolemic
environment remains to be fully resolved. Besides, although
the adverse contribution of myeloid cells in atherosclerosis is
generally accepted, it is still an open question why a strong
pro-inﬂammatory response within the arterial wall fails to be
resolved even after reducing potential inﬂammatory triggers.
Recent studies have illuminated the mechanisms underlying
the hypercholesterolemia-induced myelopoiesis and a shift-
ing towards the pro-inﬂammatory Ly6Chigh monocytes [23,24].
Hitherto, the debate has primarily focused on the link between
cholesterol accumulation within the plaque macrophage and local
ongoing inﬂammatory processes. However, myeloid priming and
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reprogramming under hypercholesterolemic conditions can occur
already within the bone marrow, due to an overload of cholesterol
and defective efﬂux pathways in hematopoietic stem and myeloid
precursor cells. Animal studies have shown that cholesterol efﬂux
pathways in hematopoietic stem cells (HSC) are mediated by
apolipoprotein E (ApoE), ATP-binding cassette transporter A1
(ABCA1) and ABCG1 and these processes are controlling HSC
expansion in the bone marrow. Transplantation of ABCA1−/−
ABCG1−/− bone marrow into Ldlr−/− mice fed a Western type diet,
as well as studies in ApoE−/− mice fed a Western type diet, induced
dramatic leukocytosis (monocytosis and neutrophilia), which
could be reversed by overexpression of the transgenic human
Apo-AI [25–27]. The proliferative response in HSC was  favored by
increased cholesterol storage into the plasma membrane (due to
impaired efﬂux), which resulted in increased expression of the
proliferative cytokine receptors to IL-3, IL-5 and GM-CSF. Recent
evidence suggests that Western type diet feeding also induces
epigenetic modiﬁcations within HSC and myeloid progenitor
subsets, potentially provoking increased myelopoiesis [28,29].
Van Kampen et al. [29] revealed in competitive bone marrow
transplantation experiments using Ldlr−/− recipients fed a chow
diet that donor bone marrow from Western type diet fed animals
markedly increased myeloid progenitor proliferation compared
to donor bone marrow from chow fed animals. Bone marrow
from Western type diet fed mice showed hypomethylation in
CpG-regions in the genes encoding PU.1 and IRF8, key regulators
of monocyte proliferation and macrophage differentiation. Con-
sistently, blood leukocyte numbers were signiﬁcantly increased
as a result of increased circulating monocytes, along with the
presence of a more activated splenic macrophage phenotype and
increased plaque sizes. In agreement with these data, Seijkens and
colleagues [28] demonstrated in a competitive bone marrow trans-
plantation study (transfer of normocholesterolemic bone marrow
cells into either chow or high fat diet fed Ldlr−/− recipients) that
a hypercholesterolemic BM microenvironment induced loss of
HSC quiescence, characterized by increased expression of cyclin
B1, C1 and D1, and skewed HSC development towards myeloid
lineages, especially towards granulocytes and Ly6Chigh monocytes.
HFD priming of bone marrow HSC remained even after transfer
into normocholesterolemic mice and was associated with reduced
H3K9/14 acetylation at the promoter of the retinoblastoma (RB)
gene (involved in the control of excessive cell growth). In summary,
these studies shed new light on the causality between hyperc-
holesterolemia, altered epigenetic patterning in HSC and myeloid
progenitors, and increased susceptibility to atherosclerosis.
Indeed, the concept of epigenetic regulation is being increas-
ingly acknowledged as an important contributor in the patho-
genesis of atherosclerosis and other metabolic diseases. Research
within the last decade has provided an essential link between
pro-atherogenic factors (amongst others diet, disturbed blood ﬂow
patterns, dyslipoproteinemia, hyperglycemia and microbiome) and
reprogramming of the epigenome (altered DNA methylation and
histone modiﬁcations) in various cell types such as leukocytes,
vascular endothelial cells (EC) and vascular smooth muscle cells
(vSMC) [30,31].
3. Trained innate immunity
Although cells of the innate immune system are tradition-
ally considered incapable of building an immunological memory,
plants and invertebrates that lack an adaptive immune system
are protected against reinfection with pathogens, suggesting that
the response of the innate immune system can be modiﬁed by
previous encounters [10]. Trained innate immune responses were
conﬁrmed in human monocytes ex vivo by showing that mono-
cytes can adopt a long-term pro-inﬂammatory phenotype after
brief exposure to various micro-organisms or microbial products,
including the bacille Calmette-Guérin (BCG) vaccine, Candida albi-
cans, or its cell wall component -glucan [32,33]. This phenomenon
could also be shown in humans in vivo by demonstrating that BCG
vaccination in healthy human subjects induced an increased pro-
duction of pro-inﬂammatory cytokines when isolated monocytes
were exposed ex vivo to various unrelated microbial metabolites
[32]. This enhanced pro-inﬂammatory phenotype of the monocyte
could be detected even three months after the ﬁrst vaccination
suggesting that trained innate immune responses can persist for
relatively long periods. The powerful immunologic effects of this
phenomenon are illustrated by the ﬁndings in scid mice, which lack
T and B lymphocytes, where BCG vaccination provided robust pro-
tection against a subsequent lethal dose of C. albicans. In humans,
BCG vaccination prior to inﬂuenza vaccination results in a more
pronounced increase and accelerated induction of functional anti-
body responses against an inﬂuenza vaccine [34].
Importantly, trained innate immunity cannot only be induced
by microbial products, but most likely also by metabolites that are
relevant in the development of metabolic diseases and its compli-
cations. In the context of atherosclerosis, innate immune training
might occur in a high fat and high cholesterol environment occur-
ring within the plaque and potentially elsewhere, such as in the
gut, liver or bone marrow. We postulate that long-term epigeneti-
cally reprogrammed myeloid precursor cells that are characterized
by a hyper-inﬂammatory phenotype may  contribute to a sustained
disease progression [35] (Fig. 1).
3.1. Human in vitro studies
In an in vitro model in human isolated monocytes, we found that
trained innate immunity can be induced by modiﬁed LDL (oxLDL
as well as acetylated LDL), but not by native LDL [36]. Twenty-
four hour exposure of human monocytes to low concentrations
of oxLDL resulted in an increased production of pro-atherogenic
cytokines and chemokines (including IL-6, TNF, IL-8, and MCP-1)
upon re-stimulation of the cells 7 days later with TLR4 or TLR2 ago-
nists. Additionally, IL-18, MMP2, and MMP9  mRNA-expression was
signiﬁcantly higher in the trained monocytes and increased foam
cell formation with higher expression of the scavenger receptors
CD36 and SR-A and decreased expression of the cholesterol efﬂux
transporters ABCA1 and ABCG1 was  found. Importantly, oxLDL-
induced trained macrophages showed no signiﬁcant differences in
expression of TLR4, TLR2 and nitric oxide synthase (‘M1’ markers);
arginase1 and CD163 (‘M2’ markers); and HLA-DR (human leuko-
cyte antigen-DR), DC-SIGN (dendritic cell-speciﬁc intercellular
adhesion molecule-3-grabbing nonintegrin), and CD83 expression
(DC markers). These data illustrate that the trained innate immune
phenotype does not merely represent skewing of the cells into
the classical ‘M1’ but rather represents a unique pro-inﬂammatory
phenotype. Pathway analysis revealed that oxLDL-induced train-
ing is dependent on TLR2 and TLR4 activation, and activation of
extracellular regulated kinase (ERK) and phosphoinositide 3 kinase
(PI3 K) [36].
3.2. in vivo studies
Corroborating the human in vitro data, it has previously been
reported that subcutaneous immunization of cholesterol-fed New
Zealand White rabbits with a human dose of BCG enhanced
peripheral leukocyte activation, aortic monocyte recruitment and
atherogenesis [37]. Although this ﬁnding ﬁts within the concept
that trained innate immunity contributes to atherogenesis, a con-
tributory role for the adaptive immune system cannot be excluded
in these experiments. In addition, several papers provide evidence
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Fig. 1. Cellular stressors can inﬂuence the epigenetic landscape of innate immune cells. Depending on the chromatin modiﬁcation the outcomes lead to different immune
responses of the cells towards secondary stimuli, a concept that has been termed ‘innate immune memory’, with alternative fates being polarization, cell death or increased
proliferation.
that glucose can also induce a persistent immunological memory in
various cell types that are relevant in the context of atherosclerosis,
including EC, vSMC, and monocytes. In a mouse model of diabetes,
long-term activation of several key inﬂammatory genes in isolated
vSMC was described, which correlated with increased H3K4 methy-
lation and suppressed H3K9 di- and tri-methylation at the nuclear
factor B (NF-B) subunit p65 promoter, which persisted even after
ex vivo cell culturing [38,39]. Also, brief exposure to high-glucose
medium in cultured EC induced a persistent pro-inﬂammatory phe-
notype, even after reversal to normoglycemic conditions. This was
associated with enrichment of the activating mark H3K4me1 in the
NF-B subunit p65 [40]. These results highlight the surprisingly
long-lasting effects that short-term hyperglycemic spikes can exe-
cute on vascular cells, suggesting the idea of memory formation
as a result of methyl-writing and methyl-erasing histone modiﬁca-
tions [41]. In line, the concept of epigenetically mediated metabolic
memory was recently also illustrated in patients from the Diabetes
Control and Complications Trials (DCCT). Isolated monocytes from
patients without diabetic microvascular complications, that had
received intensive diabetes regulation in the past, showed overall
hyperacetylation of H3K9 compared to patients with microvascular
complications who had received less-intensive diabetes regula-
tion in the past [42]. A link to glucose induced alterations in the
bone marrow niche has recently been illustrated by the obser-
vation that a high-glucose environment induces stable intrinsic
pro-inﬂammatory changes in HSC in mice [43].
Further in vitro and in vivo studies are required to corroborate
the concept of trained innate immunity due to persistent epige-
netic changes in response to ‘epigenetically toxic’ nutrient and/or
microbial metabolites such as high fat, high cholesterol or high glu-
cose in the context of metabolic diseases and its complications
including atherosclerosis. Nevertheless, one supporting issue in
the theory of epigenetic reprogramming and development of a
trained memory is the trans-generational transmission of epige-
netic traits, independently of genetically inherited risk factors [44].
In this regard, several studies in humans and experimental animal
models have shown that parental adverse diet feeding (under- or
over-nutrition) not only inﬂuences the individuals environment,
but can also inﬂuence the metabolic phenotype in the offspring
thereby raising metabolic and cardiovascular disease susceptibility
[45–48]. However, dissecting the effects induced by an unfavorable
intra uterine environment the fetus is exposed to during gestation
from direct effects on the parental germ line remains a challenging
task. To determine whether epigenetic information can be trans-
mitted through the germ line, multiple animal studies have tested
the question of whether the offspring responded to changed pater-
nal diet conditions. Indeed, paternal low-protein diet induced an
up-regulation of genes involved in lipid and cholesterol biosyn-
thesis in both male and female offspring, which was  associated
with a changed DNA methylation pattern in enhancer regions of
peroxisome proliferator-activated receptors (PPAR)  [49]. Like-
wise, chronic HFD feeding of male rats led to altered expression
of genes involved in glucose metabolism due to a changed DNA
methylation pattern, subsequently impairing glucose tolerance as
well as insulin sensitivity in female offspring [50]. A recently
published study demonstrates that a high-fat/high-fructose diet,
starting at young age, leads to the development of obesity and to
the progression of metabolic syndrome, accompanied by altered
DNA methylation patterns in male and female Wistar rats [51].
HFD feeding was shown to affect 5-mC levels differently in both
genders with a 20% reduction in males and a 15% increase in
females. Interestingly, DNA methylation patterns were modiﬁed
as well in the F1 generation, thus proposing that HFD-induced epi-
genetic modiﬁcations – as mediator of metabolic memory – can
be transmitted to the next generation, subsequently increasing the
susceptibility for disease development. Three recent studies sup-
port the idea of epigenetic inheritance by the paternal germ line
in demonstrating that nutritional change can directly remodel the
epigenetic signature of spermatozoa. A comprehensive proﬁling of
the sperm epigenome showed that mal-nutrition as well as over-
nutrition altered small RNA levels, including tRNA fragments, and
DNA methylation patterns, indicating that sperm (as the direct
transducer of genetic information) is vulnerable to environmen-
tal changes [52–54]. Whether epigenetic changes in the myeloid
lineage can be transmitted to offspring remains unanswered yet.
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4. The potential mechanisms leading to trained innate
immunity
The more prone pro-inﬂammatory phenotype that characterizes
trained innate immune cells is critically dependent on a complex
integration of epigenetic reprogramming and a change in the intra-
cellular immuno-metabolism.
4.1. Epigenetic reprogramming
Epigenetic modulation denotes the regulation of gene tran-
scription independent of the DNA sequence. Epigenetic regulation
can occur at the level of DNA methylation, histone modiﬁcations,
or involves RNA-based mechanisms. Whereas DNA methylation
is associated with a condensed chromatin structure that pre-
vents binding of transcription factors and gene silencing, histone
acetylation is associated with activation of gene transcription.
Histone methylation can either activate or repress gene transcrip-
tion, depending on the exact location of the methylated lysine
residue and on the number of bound methyl groups (mono-, di-, or
trimethylation). Macrophage differentiation, polarization, and acti-
vation can all be inﬂuenced by epigenetic reprogramming, which
is reviewed in detail elsewhere [55–57].
A distinguishing hallmark of a trained innate immune cell is its
ability to exhibit a quantitatively and qualitatively modiﬁed – usu-
ally more intense – inﬂammatory response upon re-challenge with
danger signals that differ from the priming stimulus. The underly-
ing molecular basis has thus far only partially been resolved and
involves changes in chromatin organization (loosening and strin-
gent accessibility to the transcriptional machinery), but might also
comprise alterations in DNA methylation and RNA functionality
(miRNAs, lncRNAs, tRNAs) caused by a certain primary stimulus
[58,59]. Two recent studies support the concept of trained innate
immunity in that they evidenced latent or de novo enhancer for-
mation in stimulated macrophages [60,61]. TLR4-induced NF-kB
activation in macrophages resulted in binding of the transcrip-
tion factors (TF) PU.1/C/EBP to an appropriate enhancer element.
TF binding was accompanied by recruitment and binding of the
NF-kB-p65 subunit and histone acetyltransferases, and subse-
quent RNA polymerase II binding and elongation. Finally, histone
methyltransferases MLL1, MLL2/4 and MLL3 were recruited, being
responsible for H3K4 monomethylation and fully active enhancer
formation. Notably, de novo formed enhancer elements remained
stable (H3K4me1) upon loss of stimulus, and re-stimulation of
macrophages resulted in faster and stronger responses.
For oxLDL-induced trained immunity in isolated human
monocytes, epigenetic reprogramming at the level of histone
methylation is crucial. Brief stimulation of human monocytes with
oxLDL leads to the acquirement of a ‘trained innate memory’, which
was associated with a pro-atherogenic and pro-inﬂammatory phe-
notype, and was characterized by enriched H3K4 trimethylation
– a prototypical long-term activating epigenetic mark – on the
promoters of pro-inﬂammatory cytokines and chemokines [36].
Moreover, trained innate immunity was completely prevented
by co-incubation with a nonspeciﬁc histone methyltransferase
inhibitor.
For training with -glucan, an unbiased genome-wide exper-
imental approach revealed changes in the activating H3K4me3
levels on promoters, H3K4me1 levels on enhancers, and H3K27ac
levels on promoters and enhancers. Indeed, most dynamic promot-
ers showed an enrichment of these marks [62]. Moreover, pathway
analysis of the promoters that were potentiated by -glucan iden-
tiﬁed several innate immune and signaling pathways upregulated
in trained cells that are responsible for the induction of trained
immunity.
4.2. Immuno-metabolism and epigenetic programming
Epigenetic modiﬁcations are indispensable in cell repro-
gramming, however, it still remains an open question which
cellular processes act to initiate or maintain these modiﬁca-
tions. Increasing evidence supports a close connection between
systemic and cellular metabolic processes and epigenetic repro-
gramming with a crucial role for cellular metabolites, e.g.
S-adenosylmethionine (SAM), ﬂavin adenine dinucleotide (FAD),
-hydroxybutyrate (-OHB), acetyl-CoA, NAD+, -ketoglutarate,
and adenosine triphosphate (ATP) as co-modiﬁers for epigenetic
‘writing’ (DNA and histone methyltransferases, lysine acetyltrans-
ferases) and ‘erasing’ (DNA demethylases, histone deacetylases,
lysine demethylases) enzymes [63,64]. The metabolic state of an
immune cell represents a highly dynamic process and changes
between homeostasis and immune activation (tolerance versus
inﬂammation), all of which has been documented in different
macrophage phenotypes. Generally, resting macrophages and the
‘M2’ phenotype (involved in tissue repair and wound healing)
utilize energetically efﬁcient processes including an intact Krebs
cycle with ATP generation via oxidative phosphorylation. Upon
immune cell activation and a switch towards the ‘M1’ phenotype
there is a rapid shift towards aerobic glycolysis, which enables de
novo lipogenesis, cholesterol and amino acid synthesis for subse-
quent fast cell division and growth, and an increased production
of inﬂammatory mediators (eicosanoids, IL-1, reactive oxygen
species) [65,66]. Hence, the cellular transcription machinery and its
chromatin associated proteins process cellular metabolic signals to
regulate gene expression.
The importance of immuno-metabolism in macrophage polar-
ization and reprogramming suggests that similar mechanisms
take place during the long-term acquirement of a trained innate
memory phenotype. Indeed, a shift from oxidative phosphoryla-
tion towards aerobic glycolysis through the AKT-mTOR-HIF-1
pathway, accompanied by changes in histone marks such as
H3K4me1, H3K4me3 and H3K27ac, has recently been described
to be important for training of human monocytes with -glucan.
Pharmacological inhibitors of glycolysis, such as 2-deoxy-d-glucose
and inhibitors of the mTOR pathway, such as metformin, prevented
-glucan-induced trained innate immunity [62,67]. LPS-priming
induced a shift towards aerobic glycolysis in murine macrophages,
which resulted in the accumulation of the Krebs cycle intermediate
succinate, which itself induced the expression of the inﬂamma-
tory cytokine IL-1 through the transcription factor HIF-1 [68].
These studies emphasize that Krebs cycle metabolites (such as suc-
cinate, -ketoglutarate or NAD+) are important in the induction or
inhibition of histone-modifying enzymes, thus inducing long-term
changes in the monocyte or macrophage phenotype.
How immuno-metabolism is altered under conditions of hyper-
lipidemia and which metabolites potentially contribute to the
establishment of a trained myeloid (precursor) cell phenotype
in atherosclerosis is still ill-deﬁned. Transcription factors such
as sterol regulatory element binding protein (SREBP; regula-
tion of cholesterol biosynthesis and uptake), liver X receptor
(LXR; regulation of cholesterol elimination and inﬂammation)
and PPARs (regulation of fatty acid oxidation/energy homeostasis,
lipid metabolism and inﬂammation) strictly control the balance
between systemic and cellular lipid homeostasis by regulating
genes involved in lipid uptake, storage, efﬂux, de novo lipid biosyn-
thesis and catabolism, as well as inﬂammatory processes. Excessive
lipid or cholesterol uptake by immune cells has been shown
to favor inﬂammatory processes, which accounts for the exac-
erbated outcome of diseases associated with chronic metabolic
inﬂammation (obesity, atherosclerosis). For example, overload of
modiﬁed lipoproteins (oxLDL) in liver Kupffer cells induces a con-
tinuous state of intracellular stress and promotes a switch towards
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the pro-inﬂammatory ‘M1’ phenotype [69]. Hyperlipidemia also
modulates the immune system by enhancing bone marrow and
extramedullary hematopoiesis through epigenetic reprogramming
of genes crucially involved in monocyte proliferation and differen-
tiation [29]. Somewhat unexpectedly, Spann and colleagues have
recently shown that peritoneal macrophages isolated from West-
ern type diet fed Ldlr−/− mice exhibited an overall reduction in
pro-inﬂammatory gene expression compared with macrophages
from chow fed mice, which was related to the accumulation
of desmosterol, an intermediate metabolite in the cholesterol
biosynthesis pathway and activator of LXRs [70]. Desmosterol accu-
mulation in peritoneal foam cell macrophages might be explained
by impaired functionality of desmosterol reductase, the metabolic
enzyme for desmosterol degradation. Together, these data clearly
illustrate that ﬁrstly a tight interplay between the different lipid
sensing nuclear receptors is important to balance intracellular lipid
and cholesterol homeostasis and to control immune signaling path-
ways, such as NF-kB, or Nlrp3. Secondly, the speciﬁc environment
crucially contributes to metabolic processes, which critically inﬂu-
ences inﬂammatory responses in different myeloid subsets.
5. Nutritional control of immunity
Diet and its components can activate cells of the innate immune
system, thus profoundly inﬂuencing immune responses, and poten-
tially inducing long-term epigenetic modiﬁcations and a ‘trained
innate memory’, especially within the gut resident myeloid sub-
sets. In line, the gut microbiota plays an important role in the
development and maintenance of the immune system. The micro-
biota affects immune cell metabolism and function either through
metabolites derived from its enzymatic machinery, such as short
chain fatty acids (SCFA), bile acid, or trimethylamine (TMA), or
through particular microbial molecules, such as innate immune
receptor activating ligands [71–73]. Maternal and early-life dietary
habits already play an important role in the development of the
immune system, and the prevention of immunological disorders
later in life [74]. The composition (quantity and quality) of free fatty
acids and lipids (and their oxidative metabolites) in the diet is cru-
cial in maintaining immune cell homeostasis and inﬂuences both
innate and adaptive immune cell responses. Changes in dietary
habits such as increased intake of energy-dense processed food
enriched in sugars, fat, phosphatidylcholine (PC) and L-carnitine
instead of nutrient-rich foods, induce a shift from commensal to
more pathogenic bacterial strains within the gut. These changes in
enteric microbiome composition correlate with an increased inci-
dence of immunological disorders, such as asthma, cancer, allergies,
autoimmune and cardiovascular diseases [75,76]. In contrast, diets
enriched in complex carbohydrates and high ﬁbers, such as found
in vegetables, fruits and ﬁsh, promote gut homeostasis. These diets
can beneﬁcially inﬂuence amongst others the production of antimi-
crobial peptides and mucus, maintenance of epithelial integrity
and tissue repair, production of anti-inﬂammatory cytokines and
maintenance of immune tolerance. Mechanistically, the microbial
enzyme machinery can process these ﬁber-rich food into SCFA,
including n-butyrate, propionate and acetate, and can inﬂuence
the production of other end products including idole-3-aldehyde,
niacin and omega-3 fatty acids. Besides their function as energy
sources, these metabolites control gut homeostasis by signaling
through different receptors, e.g. the Aryl hydrocarbon receptor
(AhR) and G-protein coupled receptors (GPCR), expressed on innate
lymphoid cells, innate immune cells and Tregs. Food-induced epi-
genetic reprogramming in innate immune cells has been supported
by a recent study, in which the SCFA n-butyrate led to the down-
regulation of LPS-induced pro-inﬂammatory mediators, including
nitric oxide, IL-6, and IL-12 [77]. These effects were independent
of TLR-signaling or activation of GPCRs, but were due to inhibi-
tion of histone deacetylases by n-butyrate. Overall, this rendered
lamina propria macrophages hypo-responsive and maintained a
tolerogenic environment.
Western type diets are enriched in poly-unsaturated fatty acids,
associated with dysbiosis, a state of low-grade chronic inﬂamma-
tion in the intestines through activation of NF-kB and the Nlrp3
inﬂammasome, and increased intestinal permeability resulting in
endotoxemia [78]. Indeed, studies in humans and animal models
have shown that an accumulation of lipids and cholesterol, and an
impaired lipid clearance in myeloid cells are associated with worse
septic shock outcome due to increased TLR2 and 4 activation [79].
A systemic-wide metabolomics approach has recently shown that
metabolites (choline, TMA, betaine) derived from the dietary phos-
pholipid PC or L-carnitine represent risk factors for cardiovascular
diseases. Indeed, increased systemic levels of these metabolites
correlate with more aggravated CVD phenotype [80,81]. Consis-
tent with these observations, ApoE−/− mice fed a diet enriched
in PC or L-carnitine, exhibited worsened atherosclerotic disease
outcome [80,81]. PCs and L-carnitine, enriched in red meat, eggs,
milk and certain ﬁsh, are processed by the gut microbial enzymatic
machinery to choline and TMA, which is further metabolized to
TMA  n-oxide (TMAO) by the hepatic ﬂavin mono-oxygenase (FMO).
TMAO has been shown to increase the expression of the scavenger
receptors CD36 and SR-A1 on macrophages, subsequently promot-
ing foam cell formation. Additionally, it adversely affects reverse
cholesterol transport; both processes that promote atherosclerosis.
The above-summarized data illustrate the complex network
between food composition, the microbiota and host’s metabolism
linked to immune homeostasis. Consequently, a balanced diet, rich
in ﬁbers, keeps a balanced microbiota and an intact intestinal bar-
rier function, which is a requirement for a regulated metabolism
and immune homeostasis (Fig. 2). It still remains to be resolved how
systemic to cellular immune-metabolic crosstalk, impacted by the
gut microbial composition, is working, and how this can lead to a
long-term epigenetic reprogramming.
6. Therapeutic interventions in atherosclerosis and
potential clinical relevance
6.1. Targeting LDL/cholesterol levels and inﬂammation in
atherosclerosis
So far, statins are still used as the main drug treatment in CVDs
to lower plasma cholesterol levels, thus decreasing disease burden.
However, despite the LDL lowering effect up to >50%, a signiﬁcant
residual burden of CVDs remains. Alternatively, ApoA-I containing
high density lipoprotein (HDL) is being developed as a therapeutic
agent to remove excess cholesterol from peripheral tissue, and to
dampen inﬂammation [82–85]. Studies in different animal mod-
els as well as in humans have shown the beneﬁcial effect of HDL
administration in reducing atherosclerotic plaque size [86–88].
Notwithstanding, infused HDL in two randomized controlled clini-
cal trials in human have not reached the expected beneﬁcial effects
on atherosclerosis [89,90].
In the last years scientists have searched for more intel-
ligent ways of drug delivery, but also for novel therapeutic
targets to dampen atherosclerotic lesion progression. The use
of nanoparticles seems to be an attractive therapeutic tool to
deliver anti-inﬂammatory drugs to speciﬁc cell types with the aim
to impair immune actions in certain cell subsets e.g. restricting
myeloid cell differentiation and migration of pro-inﬂammatory
Ly6Chigh monocytes to the plaque, dampening plaque macrophage
immune signaling and increasing macrophage efﬂux. Some recent
preclinical studies have successfully been proposed [91,92].
390 A. Christ et al. / Seminars in Immunology 28 (2016) 384–393
Fig. 2. Schematic representation of the hypothesis that diet can have long lasting effect on the systemic host response via epigenetic reprogramming by microbiome-derived
PAMPs  and metabolites.
6.2. Epigenetic remodeling as a potential therapeutic approach
for CVD
The recent insights into possible mechanistic links between
epigenetic cellular reprogramming and pathophysiology of
atherosclerosis could lead to novel strategies to lower CVD risk
[93,94]. Moreover, epigenetic modiﬁcations (DNA methylation pat-
tern, modiﬁed histone marks) might evolve into useful predictors
for disease stage [95] and have recently been linked to atheroscle-
rosis in humans [30,96]. Wierda and colleagues evaluated global
H3K27me3 levels, as well as levels of histone-modifying enzymes
(EZH2, BMI1 and JMJD3) in vessels representing different stages of
atherosclerotic plaque development. Overall, they notiﬁed a global
decrease in H3K27me3 in the media of more advanced atheroscle-
rotic plaques, which might reﬂect the dynamic pattern of vSMC
differentiation and proliferation associated with atherosclerotic
disease [30].
Co-modifying metabolites as well as ‘writing’ and ‘erasing’
enzymes are amenable to pharmacological modulations, and could
potentially turn into novel therapeutic targets. A few nonselective
HDAC inhibitors are already used in regular patient care in can-
cer treatment [97]. In addition, nonselective HDAC inhibitors have
shown beneﬁcial effects in animal models for arthritis, septic shock
and inﬂammatory bowel disease [98]. Preclinical studies in mice
support the idea that ‘epigenetic drugs’ may  also be a potential
tool in the treatment of atherosclerosis [99]. Administration of the
nonselective HDAC inhibitor trichostatin A (a lysine deacetylase
inhibitor) into Ldlr−/− mice induced a more exacerbated neointima
formation by increasing CD36 mRNA, protein and surface expres-
sion levels thus increasing macrophage foam cell formation.
Histone demethylases can also induce a pro-inﬂammatory
macrophage phenotype. For example, Jmjd3, UTX and Uty (which
are H3K27 demethylases) are induced upon TLR engagement and
are linked to the expression of inﬂammatory genes [100]. Target-
ing of Jmjd3 and Utx H3K27 demethylases with small molecule
inhibitors impaired inﬂammatory responses in human primary
macrophages, which is of high pharmacological interest [101].
However, Jmjd3 also plays an important role in the ‘M2’ polariza-
tion in the context of helminth infection, illustrating its dual role
dependent on stimulus and environmental context [102]. Selective
HDAC inhibitors may  be used to dampen inﬂammatory responses
within plaque macrophages. Three recent studies illuminated a
functional role for certain HDACs in the context of atheroscle-
rosis. Myeloid deletion of HDAC3, a histone deacetylase which
promotes ‘M1’ polarization [103], was shown to augment lesion
size, but lesions showed a more stable phenotype characterized
by a collagen-rich ﬁbrous cap, reduced lipid content and reduced
numbers of plaque macrophages. The more stable plaque pheno-
type was associated with increased collagen formation by vSMC
due to increased TGF- release by HDAC3 deleted myeloid cells
[104]. In addition, a genome-wide association study illustrated
the association between HDAC9 modiﬁcations and atherosclerosis
development. In fact, certain HDAC9 transcripts are more related
to coronary artery disease susceptibility [105]. Consistent with
these data, Cao and colleagues revealed a correlation between
HDAC9 deletion in bone marrow cells and limited atherosclerosis
development in the Ldlr−/− mouse atherosclerosis model. HDAC9
deletion in macrophages was  linked to an increased expression
of the cholesterol efﬂux transporters ABCA1 and ABCG1, reduced
inﬂammation, and a switch towards the ant-inﬂammatory ‘M2′
phenotype [106].
The above-mentioned studies support the impact of epigenetic
remodeling in the pathophysiology of atherosclerosis, thus encour-
aging the development of epigenetic tools for beneﬁcial lesion
remodeling. Nevertheless, it has to be noted that different isoforms
of histone modifying enzymes might have opposing effects within
the same cells, but also in different cell types. Additionally, enzymes
might function differently in healthy versus acute versus chronic
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disease stages of atherosclerosis. A tremendous challenge within
the next years will be to better understand epigenetics in the patho-
physiology of CVDs and to design cell-speciﬁc epigenetic drugs that
target cell subsets which only detrimentally contribute to disease
progression. Another important challenge will be the correct timing
of therapeutic intervention.
In addition to speciﬁc epigenetic inhibitors, further elucida-
tion of the immune-metabolic basis of trained innate immunity,
such as the metabolic shift that occurs, might provide alterna-
tive novel drug targets. Drugs that interfere with glycolysis (such
as metformin, direct mTOR inhibitors, glycolysis inhibitors) pre-
vent the occurrence of trained immunity in in vitro settings [67].
In animal models of neovascularization it has been revealed that
glycolysis inhibition limits neovessel formation [107]. A number
of small studies in patients with atherosclerosis have evidenced
the systemic anti-inﬂammatory effect of metformin [108]. In addi-
tion, metformin inhibited monocyte to macrophage differentiation,
and reduced pro-inﬂammatory cytokine production [109]. How-
ever, a real anti-atherosclerotic effect by metformin administration
has not been proven yet. Although metformin treatment reduces
cardiovascular morbidity and mortality in patients with diabetes
compared to alternative glucose-lowering agents with similar
glycemic control [110], metformin could not limit the intima media
thickening in a recent trial in patients without diabetes [111].
7. Conclusion
There is accumulating evidence that many cardiovascular risk
factors, both traditional and non-traditional (e.g. nutrients, micro-
biota), induce a long-term (epigenetic) reprogramming of cells of
the innate immune system, which in turn may  provoke a condition
of continuous innate immune cell activation. It still remains an open
question, which cellular processes act to initiate or maintain these
alterations. An increasing number of studies support the idea of
a close connection between systemic and cellular metabolic pro-
cesses and epigenetic reprogramming in the induction of trained
innate immunity. These ﬁndings pave the road for the identiﬁcation
of novel drug targets. Further mechanistic insights on the induc-
tion of trained innate immunity are necessary to make beneﬁcial
use in future clinical therapeutic applications. Especially, unravel-
ing the mechanisms in the various stages of atherosclerosis will be
a challenging task within the next years. Nevertheless, epigenetic
remodeling and the use of ‘epigenetic drugs’ are a promising tool
for future treatment of atherosclerosis.
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